CRMD - Earnings call transcript Q1 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone, and welcome to the CorMedix Inc.

First Quarter 2020 Earnings Conference Call. Today's call is being recorded.

At this time, I would like to turn the conference over to Dan Ferry from LifeSci Advisors. Please go ahead.

Daniel Ferry

to First welcome Conference XXXX and Call. afternoon, the Quarter CorMedix Earnings Good today Chief Khoso CorMedix. the is Leading call Baluch, Executive of Officer He Medical Mounts, Counsel; Phoebe Chief is President joined General and Financial Executive Officer. Paul and Officer; Vice Chief Matt David, Chew, by

may Neutrolin I within management are the the Securities forth expectations, the the what product we other meaning the future any begin, other beliefs, everyone and than Litigation company's during market as risks U.S. and but certain statements financial of include, following. limited plans Private of candidates, to revenues candidates. statements and Neutrolin like of set position, and subject potential of other would for Before are XXXX. about and the Any product Reform clinical historical remind known to that projected in and call, management's goals make statements These not Act acceptance its costs forward-looking prospects, and fact regarding including future in uncertainties are statements to, program development

for not www.sec.gov regulatory to of of free important detail described or and differ SEC, or as product product are limited of include from upon spending development projections as to statements and but candidates filings CorMedix. the are from business at projections variety the in of available anticipated expectations More risks to due which results statements estimates timing thereof, to CorMedix's may and company's as SEC's the plans Actual raising in and costs. possible results including, and related any timing, approvals or position, a clinical website at These our to, request forward-looking commercialization. about interpretations projections development manufacturing licensing plans to our market greater uncertainties the nature expectations, other capital with component charge regulatory future copies and materially actions, and specifically, cash transactions, the product and commercial and expectations clinical development, any factors, cost these

may statements. not actually note undue update statements. or the does except described to law. CorMedix now go investors ahead. should these reliance these the to Please on these plans is Mr. to call intend forward-looking not as achieve time, place goals that not please in CorMedix Baluch, forward-looking Officer Khoso, At this required my statements, of by turn it Khoso Chief Executive pleasure CorMedix. over And

Khoso Baluch

to the patients lock and CorMedix. overall update on subsequent with for the for On bringing market hemodialysis we catheter thank a topics Thank use with this everyone, progress joining first for the call. call, you pertinent us a indications, other you, plus solution is you into U.S. of expansion to today's on making CorMedix Dan. topics an several cover Good on in indication number afternoon, for will Neutrolin as

Joining me Matt Financial new David. on this Officer, call are Chief Phoebe, Paul and our

will We cover four topics.

markets and position CFO, Piper health the side Partners, to with research of I'm at having financial pleased roles wealth that Matt the of experience of Lynch and our Merrill Matt Bank on his career Bros. care majority in Weisel advisory including our the previously institutions, investment you a the like the variety Thomas of experience, America and Lehman as I'd as David. brings First, capital introduce banking Ferghana well to for Jaffrey to has Bob take been CFO new search completed. a spent inform

of communicate played key as NYU, Matt where addition, role, the strategy Ovid Therapeutics. most helping a he at company is positioning trained including the which In recently a physician effectively at

CorMedix at critical this to development. in are have pleased us We Matt join stage

is Coke seamless Matt ensure transition. fortunate that to to also assist Bob are We available a

strategic and the up Matt day, is first the ongoing started Matt's to we process bringing already activities of company. for today priorities speed have Although on

Secondly, we stated, are of application the time, the will guidance next submission. for At anticipated Neutrolin of a will our regarding once our we acceptance NDA this project approval decision rolling regarding second response communication drug maintaining receive as the in on we've new XXXX. previously for occur the from to our the file of half

Now I commercial the opportunity want address for to Neutrolin.

CRBSI reduction with cost death are enormous XX% and of stated, patients for first with care has a As for of Neutrolin over done a CRBSI we've of cost fashion CRBSI p-value with a system. previously in completed product prevention is leading hemodialysis III successfully to have imposed to specs. Phase so in XX,XXX and catheters of the health spectacular study the a in our

a program disease historically As both the result, of amount care and the the for for cost care need Neutrolin patients bundle. we the to about data significant system. This reduced Medical under technology who to the bring excited Center significantly cost so why reimbursement any has fixed referred Medicaid also the as pays health and which addresses receiving seek is to health medical a the the CMS an arrangement, better the which are impediment stage to XX% unmet new for of and of of opportunity around hemodialysis to costs our are A undergoing Services, critical for patients been CMS, renal hemodialysis. patients Care the hemodialysis. care adoption

these principle, the paid-in bundle for X necessary technology lasts products. adjustments, years. cost to determine drug reduce reimbursement can data accelerate recognition that to for this transitional treatments add-on designation for utilization issue, of the new of of program while to patient which stands is collected improve TDAPA This the TDAPA, now which costs. called a both is outside new allows care In adoption in of the program However, how has incorporate CMS and/or

been the included the dramatically CorMedix in CRBSI these However, approval of hemodialysis. reimbursement its We the full under TDAPA is application, in TDAPA as period. Neutrolin already TDAPA believe qualified beyond but FDA will and of TDAPA prevention We preparing for that and have products acceptance X-year experts in NDA. of line will which other the programs, speed approval is serving believe Neutrolin on be care of a submitted Neutrolin that for standard

other opportunity market like Neutrolin indications Now to and hemodialysis for in the use. I address for would

Phoebe the believe in XXXX. by market U.S. year to million XX As per vials opportunity approximately we hemodialysis be stated,

While that we data garner and these system, reduction the not CRBSI care under the the product TDAPA our yet have of savings infections, with coverage based reimbursement patients Neutrolin, lack cost we the regarding clinical for market believe alternatives the for can plans of discussed the share significant to the pricing health on support of potential program.

does is take indications into mind opportunity is effectively opportunity current than more oncology such FDA Our and demonstrates account indications. include substantial a to TPN, secure also doubles that alone. setting for not as to pricing or other once this value-based able there Please approval that hemodialysis market those keep CorMedix model which the in

the We preparing Neutrolin. are we the excited launch as continue for commercial process and of through begin regulatory

quickly and goal while our help are it our as and as do additions welcome well management value Matt to other efficiently shareholders. recent team, maximizing all Our to hires our goals. achieve us is and as will to necessary possible as David they

solution other with scheduled on in international our for new I'd catheter selected event branding. and begin just also lock a U.S. when brand have the topics, like the we namely markets KOL that and we turn the win our X attention to

to our where to any going uses you review Over the lock solution. must As conditional DEFENCATH And I'm had product product. the existing solution. company yet catheter for provides and spelled the and Neutrolin D-E-F-E-N-C-A-T-H, to DEFENCATH for the launched. exciting as markets time, its used such for Phoebe agency will the drug be used of will the forward. U.S., pleased as we will and the lock name us approval have and equity not discuss, In see is Canada name brand markets, very the opportunity that for brand-new to other would name FDA brand approve you received from that catheter that markets, brand Middle use. regulates the This the build the East DEFENCATH, inform as European be we name continue FDA

will Now potential infections, event the the Neutrolin. hosting for will during I'm to at microbial providing be XXXX, details resistance; call. that further moving for the with and event. XX, entering on KOL will a investors bloodstream CorMedix this be of beginning cycle The Paul noon. inform be pleased May to CRBSI; events KOL catheter-related on you

Finally, please review the XX-Q are filing that today. we

approved of $X.X of sell As Jersey to losses our through million announced, $X.X program was operating CorMedix million tax same and use we certificate commissions. net New previously the approximately net

April. in a XXXX, as We filing in and FDA. note small business NDA million. in by that a amount which $X.X reimbursed will the the that our by awarded which balance March deposit filing of waiver XX, filing was the fee on we reported XXXX think quarter was We was CorMedix FDA X, fee sheet refundable also April The

the given be to very refund quickly. and pleased were We waiver the

FDA of pro As NOL the a the Jersey position $XX.X XXXX, as million. filing result of New March was fee, reimbursement of and our forma XX, sales cash the

Chief with appointed Now let's our start Financial Officer, Matt? Matt newly David.

Matt David

thrilled welcome the company. CorMedix Khoso at for introduction. be kind I'm exciting you, to the Thank an for time warm joining such and

As at who later this to DEFENCATH a approaches all the bringing possible. year, range the potential DEFENCATH expeditiously regulatory as company approval could strategic as from patients aimed it benefit decisions, of will face

in the of the I the date speed a CorMedix the prospects gained As I accomplishments particular have and appreciation the up substantial hemodialysis this priorities, to market. to novel strategic of various coming and product been on for company

markets initiatives. As strategic everything move therapeutics and raising as spent forms I'm Khoso to capital hemodialysis the an the and broader closer companies mentioned on eager to in banker in launch to to approval team first I of advising have as investment focused company's the market. the majority into my from finance, various small career my introduction, strategy subsequent experience the of bring capital on CorMedix we

population health As system the a am physician a the enthusiastic and DEFENCATH broadly. I about executive, patient targeted prospects and for biopharma both the of care

clinical COVID-XX patients fill are are industry unprecedented for stakeholders unmet the alike needs times believer CorMedix run. biopharma in living to Companies I we with firm substantial in will value and a am the in problems, like pandemic, to and have generate aiming the run. long long the solving potential triumph that the While

Let to Khoso. me hand back

Khoso Baluch

you, Thank Matt.

to with move update Phoebe. regulatory the let's Now Phoebe?

Phoebe Mounts

filing and resulted Thank me We during us continuing granting FDA the NDA by request of is you, pandemic, the challenges FDA's fees. adjustments waiver efforts prompt appreciate has pleasure all start work in small refund business let to and coronavirus and here to our us. with the for It for of with work which again, Khoso. of a the be

continuing grateful are work the their for We effort NDA through submission process. we as

we intended of for Next, DEFENCATH the very are for happy the that market. to CorMedix solution the catheter Khoso announce mentioned, lock new as is name U.S.

name In the been medical is review part a as requirements. in is as requires a in that of distribution a of subject prior and names a went CorMedix Neutrolin as NDA Europe catheter it a commercial premarket where the as saw outside FDA U.S. approve the distinguish a strong device drug, the U.S. to is to U.S., brand Neutrolin that regulated in proprietary for to for believed product rigorous know, you an name would markets new select new solution launch. an opportunity As identify CorMedix marked process has that of through lock potential FDA FDA's to it the several drug the product the the regulating CE meet of

with avoiding premarket aspects are intended compliance and proprietary errors medication the The to evaluates minimize promotional the both evaluations part to by product's review name. promotional and of claims. safety process, ensure implied As proposed requirements FDA of

the sound-alike For when forward of FDA approval to the medication is the prevent by dispensing FDA approved. the the of drug and NDA patient. administration to a the prescribing, proprietary and look-alike product look in to errors as final We example, name DEFENCATH conducts analyses

updates, the for for you the in know DEFENCATH to our initial for in has secure submitting from drug as on focus marketing application been use indication Next, the new hemodialysis previous patients. authorization primary for modules U.S.

for once in a acceptance Khoso submission. second of will of NDA we of our rolling guidance are our anticipated stated, we from the to regarding our time, the the received filing regarding of the As this maintaining At public approval have response an NDA next communication XXXX. decision file FDA occur a half

in patients, patients in Finally, regulatory parenteral the for submission to for working of indications developing addition oncology are total the preventing nutrition, for the hemodialysis catheter-related for NDA on additional continuing in pathway adult and patients TPN. bloodstream we use requiring or with infections

the with central While we securing for patients pediatric on patients focus the data patients the in for indication with protocols first catheters. indications use use we for expanding hemodialysis in are LOCK-IT-XXX, from the venous and adult developing other hemodialysis

event. KOL pass Paul? floor me cover to let Paul, summary, that With to the the

Paul Chew

Good COVID-XX historically world planned designed for hemodialysis afternoon, But webinar I'm is constant patients hemodialysis catheters. May new Today's back infection. XX, you now? the Phoebe. in have patients on threat preventable existing central threatens with Thanks, venous the everyone. the event with the infection on pleased share of and infection a in with exciting webinar and life-threatening the importance be new to catheters. investors. of pandemic The Why preventing and is shows we nothing

COVID-XX fact, the pandemic life-threatening organisms last-resort antibiotics. early in the together clinics at immunocompromised In to a are threat they for was hemodialysis time. Every resistant day, reported seated in closely from of face for patients infection, especially hours

experienced of This unmet XX webinar is hemodialysis X hemodialysis of XX medical the who the address catheter patients. patients hemodialysis the highlight vulnerable X-hour on of daily potential Eastern, to will the prevention a challenges patients, the May resistance in Now noon catheter the focus in leaders. to antimicrobial importance CorMedix for broadcast threat key infection challenges. with the needs time infection of DEFENCATH the type hemodialysis to of clinic to and both opinion is and on most the prevention webinar will these

able following available website, of Cornell to The available Long from will for NYU and answer from Weill Lehigh the Polsky Medicine call many I Island questions of Medicine; Health will Winthrop Bruce Valley Reidenberg The Hospital; and Kopyt hope School feature attend. on Network. press Nelson Bruce Dr. the and the the be Dr. Dr. invitation and from you the They'll are webinar webinar. release CorMedix to be

With that, Khoso. the let floor me to back turn

Khoso Baluch

the DEFENCATH is health you, goal material goal in All will Thank very decision maximize one in the forward refining hiring U.S. whether build-up mind. to a shareholders' an strategic commercialize NDA. we our to This stated, and closer by partner. in market, hemodialysis and preparing as DEFENCATH is payer with anticipated provider fill our to as Paul. functions [indiscernible] value. building area. continue we senior on gradual began in our And preparations evaluated with commercial or be roles We individuals the or plans launch commercial Because on with move concentrated move options our own a table for to

the Followed of hiring weeks, sales we to by payer additional of course incrementally Over team teamed the the the roll expanded with end scenario, a access commercial the team several who last have message build goal to We experts. year. with intend market force, at out field strategic the the up or over the partner.

to our to provide payers, the We up deal are step CorMedix in foundation energy approval. with market with and now dialysis within of focus required This in soon provider NDA [indiscernible] will with position contact including after large direct stakeholders a specifically great through and as the the dialysis various engaging the strong launch as a possible the CMS.

a very again, Once need. let huge you market me the represents medical large remind that unmet

CRBSI the I the standard therefore in rapidly will should the approved be the of by prevention DEFENCATH As FDA, agents in venous the become for it central in believe today, approved of pharmacological care no there are U.S. U.S. catheters.

provide XXXX. Now with line review let you of the quarter a top me first

mentioned, $XX.X to as As restricted I the is of and containing complete XX, our cash results. read I of Total a $X.X you cash million. information on report previously more million, investments XXXX, for on financial discussion short-term March excluding hand urge

of by $X.X raising use price facility at selling per selective made approximately company the $X.XX average quarter, shares net of million an of the share. about commissions During on XXX,XXX program, approximately

of Additionally, certain million proceeding approximately $X.X the we in exercise received from warrants.

of tax commissions. that we the $X.X million net losses of announced operating sale approximately million approved and $X.X to program certificate Jersey sell net raised through We were New also our

received were in funds April. These

April preparation small With of the of by after forma as fund, XXXX, fee, the including March refunded fund FDA. $X.X launch pro the connection with We resources received we FDA that of operations $XX.X filing believe million that NDA waiver from commercial we in million. XX, we plus quarter sufficient approval in second the these XXXX, cash initial the of have the business of into position a to for DEFENCATH have

e use cash during as operations, defined spend, in $X cash as quarter the million first complete XXXX. For

large the was represented June While to activities. quarter, plus substantially a approximately incremental this fees, that refundable expense, support higher primarily of filing portion was than previous the $X.X million bond by pre-launch of

fee, likely of sale refunded next is rate for after we impact the commercialization Excluding to of continue the manufacturing NDA increase going DEFENCATH our commenced over preparation the the filing quarters approval. for as modestly X and

from have focused are last work the which months. key this hopefully Matt, coronavirus turn with that now re-emphasize. Phoebe we and want into the me into making on insight the and pleased I'm challenges about the What let are occurred provide we I pandemic. takeaways efforts Paul by call. to with X covered despite imposed you progress So over you

as we that that has delighted on with process regulatory the approval make I'm the of are forward prepared First, joined track. pleased for FDA we is Matt Two, CorMedix DEFENCATH. effort the extremely to

of anticipated maintaining on half XXXX. We the in NDA for the of our are an approval guidance decision second

We plans. are provides appropriately name. the finally, this of company FDA name. funded continuing pleased a opportunity tremendous financial from which grow available explore the with strategy, the to with ensure This DEFENCATH to we're the is is conditional around brand alternatives process And to to execute to us equity on our our start approval

current sufficient of and loan [indiscernible] some a cash Our infrastructure. bid is leadership commercial fund portion to to the for of required

for catheter, intending focused TPN hemodialysis to reminder are are a additional and Finally, market, seek the patients. initially indications in DEFENCATH on oncology that while we we used

protocol are and discussions patient previous for clinical have in use of regulatory pathway catheter finalizing the had the for the oncology trial a goal of We working solution these design groups. to on TPN FDA with the with develop and lock

once it standard approved, to is infections value. shareholders' is hemodialysis become to that patients. Our maximize for preventing will believe continue catheter-related bloodstream DEFENCATH of care I goal in the

the skills experience. in process the strategic the management bring each the the discussed, The with U.S. to our unique of of margin Phoebe has moving through team and productive of quarters strength needs. will very area regulatory a team, mix last year required over approval. diligent members of in very coming DEFENCATH As a team securing continue I'm evolve on with pleased been focus

updates you move we to and embarked a continue I CorMedix. years The ago release me material for you you. Thank will support with to development call. an Thank continued call strategy your ever-increasing operator. providing of website, the look CorMedix at on press pace. the conference And few forward forward hand via back to let

Operator

Instructions]. [Operator

First question from Andrew with Riley D'Silva FBR. B.

Andrew D'Silva

Just a me. for couple of quick ones

on today, and ability I think to interested if so was And later you on little to any, stock-based talent? has a that, just COVID-XX? it. pulling the amortization mentioned an as out give approval? disruption continue be to then able for closer while impact, And it been identify your your Have me have you're to marketing. Or I depreciation to would you of appropriate I'm what let quarter? and to due to you color specifically you and but XX-Q could there expect sales COVID-XX's just onboard might acquire substantial that been members just know Could bit a you comp relates

Khoso Baluch

Thank Yes. Andy, your you, for question.

any up part you then do would you have will call this I of still we follow to your submitted, post there. questions XX-Q and answer question, suggest we with you if look in a The our have that first if

hiring middle New in relates their Bulky also March of work Matt report there And we remotely employment we're during we in Height interest giving As that but a and of to setting. been to and the some this we are further closed one home, our we other very work you I've background. we the it COVID-XX, families, see, individuals office and individuals outlined. as are to been is them, have period. have Jersey continuing from sporadically of In can hiring our remote

meetings ability done There's specifically, moment. And our and a programs continue video moved the to to impacted face-to-face lot conferencing, we've hiring our forward. conferencing job. capabilities, at not our video did pretty of move to in it a of good has and that terms So

Andrew D'Silva

And lot reiterating had TDAPA? related qualify just to anything remarks. that to Did Or new on should you Great. it were you commentary just as Great. you your TDAPA, effectively the to Okay. evolve be belief relates a of that under able during it? prepared

Khoso Baluch

firm our reimbursement we brought as also the board where stand just once eligible and individuals that opportunity to continues and space. one, an environment, to but on in coding tires TDAPA. experts And Number have we market approval. company begin TDAPA in belief very we expect access and are to keep the from discussions externally And have continue reiterating have be the internally moving we payer to not they be had get to the on to have daily firm TDAPA to the that with aspects, will belief NDA we

Andrew D'Silva

DaVita COVID-XX great of now. it regulators FDA And of The has facility the That discussions be to and that's just or earlier NDA, related Absolutely. would likes as discussion together. around U.S. your me. Fresenius? relates questions anything the to COVID-XX be And ex with just to relevant everything And Has just kind any inspections? restrictions partners, for the then that released potential your of to extremely see. changed X or has diseases lumping right infectious with

Khoso Baluch

back cover far Phoebe, concerned. will other the as respond to the And discussion. Okay. then I'll please comments ask are I come as and you regulatory FDA to

So Phoebe?

Phoebe Mounts

Yes. for Andy. Thank the you question,

the follow-up facility U.S. not have in FDA suggest ex any any We or had not be to will delays will from inspection. that there

travel I at around very we is under So can as the things still much everyone moment, But know, restrictions. think you hoping turn is that quickly. FDA

Khoso Baluch

question about to with Andy, And dialysis discussions providers. your

Obviously, We the are prime whole individuals, the large of present. not discussions are always substance at time providers. for a having discussions range those of including with dialysis

more here have specific ourselves as provider during in setting we get the the also U.S. CMS we with to prepared remarks, I once discussions in we of prepare deeper DEFENCATH said As the approval individuals with or for and go the but continue approval we dialysis will forward and

Operator

questions would Dan to further like this to back I over the additional questions. no . in turn call at the some Ferry queue, time, with for And

Daniel Ferry

today's some investors, Thank call. from the you, have up leading received questions I we that earnings to Operator. have audience, from

The first you that going is Paul. new this any information for one referenced? is during be KOL shared event Paul, to there

Paul Chew

KOL We're uncharted of will provide clinical information Thanks, next territory challenges for is vulnerable through has experts. the through thoughts facing and COVID-XX, analysts Dan. current hemodialysis CRBSI. medical event as investors moving The well opportunity KOLs our with and to perspective investors these will very share need. week the and impacted patients patients our patients, KOLs from going an are talk this for to to as own the on This market who their and have their this

Daniel Ferry

Great. Thanks, Paul.

The past, not the do is CFO you you think this can question been a Matt. Matt, do as you in second role? have why for

Matt David

No question. to the Sure. Sure. take problem. Happy

years, experience with it. a of my and part responsibilities many with care and investment go with for I worked that CFOs, as many the health As closely banker I'm familiar role

said last company, a at I the experience markets and CorMedix responsible of public for Investor Relations. be particularly recently here. a including Strategy within years the as companies, Ovid Therapeutics, adviser strategic most financing as strategy was and I've of Head may now where couple capital relevant is Given company, where working

the helps. of transition. a hand and Lastly, during talented support Hope I'm close grateful team that Bob's at to have experience this

Daniel Ferry

Matt. Thanks,

you. couple have I Okay. And Phoebe, for a

rolling the rolling the each is what submission? is And with Phoebe, So section the submitted? is as value FDA of it if reviewing submission, the not,

Phoebe Mounts

Dan. program rolling of and for submission FDA's you. provides modules. the review rolling are questions, good both Those Thank

address submission CRBSI FDA agency's us the the need of appreciate the grateful reducing So possible hemodialysis that quickly and to the patients. us the granted review we're program medical and as unmet help very for efforts to rolling opportunity use as

and to as of provide modules real the begin received. is efficiency is sponsor on FDA to module related can is FDA and it intended value sponsor the time-saving question or additional for request for sections information of the submission needed respond of rolling preparation then and Thanks on For submit completed, the it second works The as the modules responses and agency you. it the as submission from to and in and while information additional request information reviewing the the additional both information it's submitted to review, FDA. can the time. the can

Daniel Ferry

Thanks, NDA submitted? Phoebe. few can And have why imagine, have What modules tell And you has here. a filing? when been you of the us I percentage more completed as not the

Phoebe Mounts

noted. sure past on in of to I'm be ongoing as everyone -- an I as during information the the the significant FDA the there a as submitted has is information is is dialogue just amount that it modules, interest the the on critical to is complete really the progress review that the for appreciate We in FDA the NDA submission our has and knows, we're of but deemed when it. calls, FDA Well, your for accepted with process, NDA filing because said I needs NDA, there for sufficiently

priority and preparation submit and prepare for the work you all you. imperatives to we aware I that diligently Thank on the a of So are is CorMedix, NDA can to information. the assure

Daniel Ferry

potentially XXXX? believe the you one get of Great. time. second your still one. you And Phoebe, for half that Do can last again Thank approval you in

Phoebe Mounts

an decision in anticipated second the on NDA are XXXX. guidance for of At maintaining half the approval of this time, our we

sure and very complete expectations the review. focused DEFENCATH. discussions We the safety the agency's efficient FDA effectiveness that an are make as NDA in manufacturing information provides that We all evaluate and of well to cognizant all to of to in understood is required XXXX on we ensure of as preparing with the format an FDA's

XXXX. submission half assisting to of of the by that and efficient completeness to the that in believe quality approval also achieve attentive are we We the an review FDA being the second process enable to

Daniel Ferry

your have do Matt, going Okay. you're you you I guys do plans? What another is, need one not dilute the The to question us? your Phoebe. have going are Thanks, term? therefore, financing a you. rate. Are in to burn And for near cash cover to to

Matt David

to that take is one. Sure. Matt David. Happy This

have have that XQ sufficient of stated we We into cash 'XX.

As any these shareholder routes value the while mind. biopharma towards and in we'll have evaluate company, maintaining company funding multiple alternatives we

potential financing to discuss not or Beyond that, or timing related to specifics strategic are we activities. going other

Daniel Ferry

Have Great. final any Thanks, question spoken strategic talked or you. Khoso, to And for partners? one Matt. you

Khoso Baluch

have your that Pleased will matters, I provide is of we required. shareholders, any stated question, discussions any until Thank of and that to our publicly whatever Clearly, in part looking previously information of answer that will best you. is interest the pursue includes Dan. when such actively or disclosure not and strategic partners. we at

Daniel Ferry

are Khoso, back it Those like this that call. you, turn on based Okay. over for I prepared activity have leading Thank the you, closing to I'd up Khoso. the questions to remarks. to

Khoso Baluch

Thanks, Dan.

market, DEFENCATH on strategic U.S. you to infection coronavirus for protection a more committed with need a partner your patients even So own the good life-threatening during bringing to Goodbye. or all CorMedix its preventing time Thank infections. attention, apparent and importance and have The the or whether your evening. of in is pandemic. remains of to from help commercial

Operator

conference. does participation. conclude this again, And today's your thank We you for

disconnect. now may You

CorMedix (CRMD) 11 May 202020 Q1 Earnings call transcript